alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 38 studies matching “financial” in Health systems and care delivery (page 1 of 2) · 31,380 in the whole library · How the 0–100 score works

Download bibliography of these 38 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,851 studies have no institution on record and are not counted here.

What “Health systems and care delivery” covers

Health systems and care delivery — How health systems organise, coordinate and pay for dementia care, and where and how people with dementia actually receive it.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Effect of a Financial Incentive Scheme for Medication Review on Polypharmacy in Elderly Inpatients With Dementia: A Retrospective Before-and-After Study

✓ Peer-reviewed alzhub usefulness score 28 out of 100. Journal of patient safety 2024-10-18

Polypharmacy is an important healthcare issue, especially in elderly patients with dementia. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Real-world lecanemab adoption in Japan 1 year after launch: Insights from 311 specialists on infrastructure and reimbursement barriers

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-10-20

Lecanemab was approved for early Alzheimer's disease in Japan, with ≈ 6000 patients treated in the first year post approval. 2 key findings →

Participants: 6,000 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Deconstructing Heart Failure Disease Management

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Annals of Internal Medicine 2004-10-19

DeMonte Jr., MD, Joshua Chodosh, MD, MSHS, Xinping Cui, PhD, Stefanie Vassar, MS, Naihua Duan, PhD, and Martin Lee, PhDReduced Health Care Costs Associated With Disease Management for Chronic Heart Failure: A Study Using Three Methods to Examine the Financial Impact of a Heart Failure Disease Management Program Among Medicare Advantage EnrolleesEffects of Nurse Management on the Quality of Heart Failure Care in Minority Communities A Randomized TrialJane E. 1 key finding →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Current practices by Alzheimer's Disease Research Centers to remunerate research participants

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-01-27

Recent guidance from the National Alzheimer's Coordinating Center (NACC) recommends remuneration for all Alzheimer's disease (AD) research participants. 5 key findings →

Design: longitudinal study Participants: 29 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Advancing Early Detection of Alzheimer Disease in the Primary Care Setting in the United States

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Neurology. Clinical practice 2025-12-25

As evidence supporting the robustness of blood-based biomarker (BBM) testing for Alzheimer disease (AD) continues to emerge, understanding the perceptions, drivers, and barriers to the adoption of these tests among primary care physicians (PCPs) in the United States is crucial for improving patient outcomes and advancing clinical management of AD. 1 key finding →

Design: cross-sectional Participants: 603 Evidence: low

Full summary, score breakdown and related studies → Original source

Key lessons to improve care—factors contributing to delayed discharges and cost implications: medical conditions and rehabilitation delays at a tertiary rehabilitation center in Saudi Arabia

✓ Peer-reviewed alzhub usefulness score 48 out of 100. International Journal for Quality in Health Care 2024-04-01

TBI had the highest percentage (37%) compared to other conditions, which may be attributed to the prevalent challenge of cognitive impairment in TBI in addition to physical disability. 5 key findings →

Design: cohort study Participants: 2,285 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Risk Adjustment for Alzheimer Disease and Related Dementias in Medicare Advantage and Health Care Experiences

✓ Peer-reviewed alzhub usefulness score 46 out of 100. JAMA Network Open 2026-03-13

Among 5353 MA beneficiary observations (1239 [23.1%] aged 65-74 years; 3127 [58.4%] aged ≥75 years; 1785 male [33.3%]), 1629 (30.4%) reported a diagnosis of ADRD, and 3724 (69.6%) did not report an ADRD diagnosis. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Dementia diagnostic deserts: workforce and geographic inequities in the diagnostic pathway for cognitive impairment

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Health affairs scholar 2026-05-29

As disease-modifying therapies for Alzheimer's disease become available, ensuring equitable access to timely and accurate diagnosis of cognitive impairment is critical. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Effects of Changes in Multiple Chronic Conditions on Medical Costs among Older Adults in South Korea

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Healthcare 2022-04-15

This study aims to analyze the relationship between cognitive function and out-of-pocket cost of the state change of multiple chronic conditions in individuals aged 60 or older. 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Out of Pocket Costs for People with Dementia: A Comparison Across Insurance Types

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Innovation in Aging 2025-12-01

Among PWD with Medicaid, out-of-pocket costs for nursing homes and assisted living facilities were significantly higher (60%) compared to those TM (33%) and MA (30%). 5 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

After Risk-Adjustment Change, Dementia Diagnoses Increased In Medicare Advantage Relative To Traditional Medicare

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Health Affairs 2025-01-01

In 2020, the Centers for Medicare and Medicaid Services reintroduced Alzheimer's disease and related dementias to its risk-adjustment payment model for Medicare Advantage (MA) plans. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The impact of the implementation of a national policy on dementia on healthcare costs in older patients with dementia in Korea: a quasi-experimental difference-in-difference study

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Lancet Regional Health - Western Pacific 2024-01-27

Policy implementation was associated with a significant decrease in patient out-of-pocket cost. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

[Optimization of the work of outpatient memory clinics from the perspective of value-based healthcare-An approach from the Clinic for Psychiatry and Psychotherapy of the ZI Mannheim]

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Der Nervenarzt 2025-11-20

Value-based healthcare (VBHC) is a concept in health economics that aims to improve patient care through needs-oriented treatment approaches while considering the costs incurred. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

HEDIS Measures for Geriatric Care Quality: Evidence, Equity, and a Governance Framework

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Zenodo (CERN European Organization for Nuclear Research) 2023-01-30

The Healthcare Effectiveness Data and Information Set provides the dominant quality measurement framework for Medicare Advantage and commercial health plans, yet HEDIS lacks validated geriatric-specific quality indicators, equitable measurement standards for diverse older adult populations, and governance controls calibrated to the high-stakes Star Ratings financial incentive context. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Equity and budget challenges associated with the employment of anti-amyloid monoclonal antibodies for early Alzheimer's Disease in Italy: A scenario analysis

✓ Peer-reviewed alzhub usefulness score 38 out of 100. JAR life 2026-06-17

Anti-amyloid monoclonal antibodies (lecanemab and donanemab) represent the first disease-modifying therapies for early symptomatic Alzheimer's disease (AD)- Italy's National Health Service (SSN) must determine whether to include these therapies within Essential Levels of Care (LEA), requiring reimbursement across all regions. 5 key findings →

Participants: 42,000 Evidence: low

Full summary, score breakdown and related studies → Original source

Healthy Aging Brain Center improved care coordination and produced net savings

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Health affairs (Project Hope) 2014-04

Over the past two decades the collaborative care model within primary care has proved to be effective in improving care quality, efficiency, and outcomes for older adults suffering from dementia and depression. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Disparities in High-Risk Medication Use—Implications for Health Equity and Deprescribing Practices

✓ Peer-reviewed alzhub usefulness score 36 out of 100. JAMA Network Open 2025-04-14

Potentially inappropriate medication (PIM) use-defined as the use of high-risk medications that can increase the risk of adverse events such as physical, cognitive, and functional decline; delirium; hospitalizations; and mortality-remains a significant concern in older adults in the US.Numerous guidelines, including the American Geriatrics Society Beers Criteria 1 and the STOPP criteria, 2 define PIMs as medications for which the risk of adverse effects outweighs potential benefits or are inappropriate for specific populations or disease states, such dementia or kidney disease.PIM use may be particularly harmful in populations experiencing other health care disparities, as communities experiencing other consequences of health care inequity, including limited access to physicians or pharmacies, greater financial stress, and a higher comorbidity burden, may experience disproportionate effects from the adverse consequences of PIM use. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Impact of fee-revision policy for gastrostomy on its implementation among older adults with dementia in Japan

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Public health 2023-12-21

This study aimed to evaluate the impact of the policy to reduce the reimbursement fee for percutaneous endoscopic gastrostomy (PEG) on the number of PEG procedures performed among older adults with dementia. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events